Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Scientific Officer | September 11, 2026 | September 15, 2026 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,647 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 3,587 · Balance 24,583 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 1,936 · Balance 22,647 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Voyager Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 21:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,936 | $156.22 | $302,441.92 |
DisclosureSEC source: 0001894425-26-000020 · wk-form4_1789506418.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,647 F2 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 3,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000020 · wk-form4_1789506418.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,583 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Read SEC document |
| August 04, 2026 Filed Aug 5, 2026 21:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 2,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000018 · wk-form4_1785965748.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,996 F1 · kind: This transaction represents a gift/charitable contribution effective August 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-26-072922 · tm2617547-4_4seq1.xml · derivative · entry 1 Onyia Jude · CIK 0001894425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:34 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 2,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000014 · wk-form4_1781040880.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,405 F1 · kind: This transaction represents a gift/charitable contribution effective June 5, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 11,000 | $0.00 Strike: $84.74 | $0.00 |
DisclosureSEC source: 0001894425-26-000012 · wk-form4_1780438094.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,268 Underlying: Common Stock · 11,000 shares Expires 2031-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 11,000 | $160.25 | $1,762,710.40 |
DisclosureSEC source: 0001894425-26-000012 · wk-form4_1780438094.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,846 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 11,000 | $84.74 | $932,140.00 |
DisclosureSEC source: 0001894425-26-000012 · wk-form4_1780438094.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2026 Filed May 29, 2026 22:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 11,000 | $0.00 Strike: $84.74 | $0.00 |
DisclosureSEC source: 0001894425-26-000010 · wk-form4_1780092580.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,268 Underlying: Common Stock · 11,000 shares Expires 2031-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. Read SEC document |
| May 27, 2026 Filed May 29, 2026 22:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 11,000 | $155.53 | $1,710,865.20 |
DisclosureSEC source: 0001894425-26-000010 · wk-form4_1780092580.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,846 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.47 to $156.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 27, 2026 Filed May 29, 2026 22:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 11,000 | $84.74 | $932,140.00 |
DisclosureSEC source: 0001894425-26-000010 · wk-form4_1780092580.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 00:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 3,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000007 · wk-form4_1771891938.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,670 F1 · kind: This transaction represents a gift/charitable contribution effective February 20, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 9,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 13 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,669 Underlying: Common Stock · 9,669 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 55,119 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 12 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,119 Underlying: Common Stock · 55,119 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 11 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,717 Underlying: Common Stock · 2,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 10 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,380 Underlying: Common Stock · 2,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 10,755 | $124.12 | $1,334,910.60 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 8 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,780 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 19,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 7 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,535 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,466 | $124.12 | $181,959.92 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 6 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,600 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 5 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,452 | $124.12 | $180,222.24 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 4 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,349 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 9 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,681 Underlying: Common Stock · 2,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,426 | $123.10 | $175,540.60 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,111 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000003 · wk-form4_1770159672.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and vested as to 238 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and vested as to 238 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 142 | $136.06 | $19,320.52 |
DisclosureSEC source: 0001894425-26-000003 · wk-form4_1770159672.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,977 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:01 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000003 · wk-form4_1770159672.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2025 Filed Dec 2, 2025 22:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 4,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-25-000010 · wk-form4_1764713695.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,426 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award. Read SEC document |
| November 29, 2025 Filed Dec 2, 2025 22:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 2,248 | $152.16 | $342,055.68 |
DisclosureSEC source: 0001894425-25-000010 · wk-form4_1764713695.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,881 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 29, 2025 Filed Dec 2, 2025 22:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-25-000010 · wk-form4_1764713695.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:28 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-25-000005 · wk-form4_1757021325.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,703 F1 · kind: This transaction represents a gift/charitable contribution effective September 3, 2025. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 20:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 3,116 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000164 · wk-form4_1754598566.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,173 F1 · kind: This transaction represents a gift/charitable contribution effective August 5, 2025. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:01 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 59,819 | $0.00 Strike: $84.74 | $0.00 |
DisclosureSEC source: 0000914475-25-000151 · wk-form4_1752267655.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,268 Underlying: Common Stock · 59,819 shares Expires 2031-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:01 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 59,819 | $130.46 | $7,803,687.65 |
DisclosureSEC source: 0000914475-25-000151 · wk-form4_1752267655.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,289 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $131.45. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:01 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 59,819 | $84.74 | $5,069,062.06 |
DisclosureSEC source: 0000914475-25-000151 · wk-form4_1752267655.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 20:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 20,362 | $0.00 Strike: $84.74 | $0.00 |
DisclosureSEC source: 0000914475-25-000149 · wk-form4_1751919019.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,087 Underlying: Common Stock · 20,362 shares Expires 2031-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. These options will expire ten years from the date of grant on November 29, 2031. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 20:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 20,362 | $130.13 | $2,649,737.60 |
DisclosureSEC source: 0000914475-25-000149 · wk-form4_1751919019.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,289 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes an aggregate of 200 shares purchased on February 28, 2025, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 20:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 20,362 | $84.74 | $1,725,475.88 |
DisclosureSEC source: 0000914475-25-000149 · wk-form4_1751919019.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:04 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001104659-25-056565 · tm2517191-6_4seq1.xml · derivative · entry 1 Onyia Jude · CIK 0001894425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · derivative · entry 8 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,070 Underlying: Common Stock · 2,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, and will vest as to 2,690 shares on February 13, 2026, 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award. F9 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, and will vest as to 2,690 shares on February 13, 2026, 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · derivative · entry 7 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,434 Underlying: Common Stock · 2,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F8 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, and will vest as to 2,717 shares on February 13, 2026, and 2,717 shares on February 13, 2027, subject to the terms and conditions of the award. F8 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, and will vest as to 2,717 shares on February 13, 2026, and 2,717 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,447 | $116.75 | $168,933.05 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · nonDerivative · entry 4 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,089 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · nonDerivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,432 | $116.83 | $167,305.57 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,846 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · nonDerivative · entry 1 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 10,241 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · derivative · entry 6 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,241 Underlying: Common Stock · 10,241 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 54,645 | $0.00 Strike: $117.18 | $0.00 |
DisclosureSEC source: 0000914475-25-000067 · wk-form4_1739576102.xml · derivative · entry 5 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,645 Underlying: Common Stock · 54,645 shares Expires 2035-02-12 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000027 · wk-form4_1738709457.xml · derivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238 Underlying: Common Stock · 238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and will vest as to 238 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and will vest as to 238 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 126 | $152.97 | $19,273.98 |
DisclosureSEC source: 0000914475-25-000027 · wk-form4_1738709457.xml · nonDerivative · entry 2 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,561 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.99 to $154.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.